The balance between Th17 cells and regulatory T cells(Tregs)has emerged as a prominent factor in regulating autoimmunity and cancer.Th17 cells are vital for host defense against pathogens but have also been implicated...The balance between Th17 cells and regulatory T cells(Tregs)has emerged as a prominent factor in regulating autoimmunity and cancer.Th17 cells are vital for host defense against pathogens but have also been implicated in causing autoimmune disorders and cancer,though their role in carcinogenesis is less well understood.Tregs are required for self-tolerance and defense against autoimmunity and often correlate with cancer progression.This review addresses the importance of a functional homeostasis between these two subsets in health and the consequences of its disruption when these forces collide in disease.Importantly,we discuss the ability of Th17 cells to mediate cancer regression in immunotherapy,including adoptive transfer and checkpoint blockade therapy,and the therapeutic possibilities of purposefully offsetting the Th17/Treg balance to treat patients with cancer as well as those with autoimmune diseases.展开更多
Background: PD-1 and PD-L1 inhibitors have emerged as promising treatments for patients with head and neck squamous cell carcinoma (HNSCC).Methods: Systematic review and meta-analysis of PD-1 and PD-L1 inhibitors in H...Background: PD-1 and PD-L1 inhibitors have emerged as promising treatments for patients with head and neck squamous cell carcinoma (HNSCC).Methods: Systematic review and meta-analysis of PD-1 and PD-L1 inhibitors in HNSCC. Outcomes: median overall survival (mOS), median progression-free survival (mPFS), Response Evaluation Criteria in Solid Tumors (RECIST) and treatment-related adverse events (TRAEs).Results: Eleven trials reported data on 1088 patients (mean age: 59.9 years, range: 18-90). The total mOS was 7.97 months (range: 6.0-16.5). Mean mPFS for all studies was 2.84 months (range: 1.9-6.5). PD-1 inhibitors had a lower rate of RECIST Progressive Disease than PD-L1 inhibitors (42.61%, 95% confidence interval [CI]: 36.29-49.06 vs. 56.79%, 95% CI: 49.18-64.19,P < 0.001). The rate of TRAEs of any grade (62.7%, 95% CI: 59.8-65.6) did not differ.Conclusions: Meta-analysis shows the efficacy of PD-1 and PD-L1 inhibitors in HNSCC and suggests a possible difference in certain RECIST criterion between PD-1 and PD-L1 inhibitors. Future work to investigate the clinical significance of these findings is warranted.展开更多
基金supported in part by NIH Training grant T32 GM08716 to H.M.K.,NIH Fellowship grant F31 CA192787 to S.R.B.,NIH Training grant T32 AI132164-01 to C.J.D.,NCI Grants R01 CA175061 and R01 CA208514,KL2 South Carolina Clinical&Translational Research grant UL1 TR000062,ACS-IRG grant 016623-004 and MUSC Start-up funds to C.M.P.
文摘The balance between Th17 cells and regulatory T cells(Tregs)has emerged as a prominent factor in regulating autoimmunity and cancer.Th17 cells are vital for host defense against pathogens but have also been implicated in causing autoimmune disorders and cancer,though their role in carcinogenesis is less well understood.Tregs are required for self-tolerance and defense against autoimmunity and often correlate with cancer progression.This review addresses the importance of a functional homeostasis between these two subsets in health and the consequences of its disruption when these forces collide in disease.Importantly,we discuss the ability of Th17 cells to mediate cancer regression in immunotherapy,including adoptive transfer and checkpoint blockade therapy,and the therapeutic possibilities of purposefully offsetting the Th17/Treg balance to treat patients with cancer as well as those with autoimmune diseases.
文摘Background: PD-1 and PD-L1 inhibitors have emerged as promising treatments for patients with head and neck squamous cell carcinoma (HNSCC).Methods: Systematic review and meta-analysis of PD-1 and PD-L1 inhibitors in HNSCC. Outcomes: median overall survival (mOS), median progression-free survival (mPFS), Response Evaluation Criteria in Solid Tumors (RECIST) and treatment-related adverse events (TRAEs).Results: Eleven trials reported data on 1088 patients (mean age: 59.9 years, range: 18-90). The total mOS was 7.97 months (range: 6.0-16.5). Mean mPFS for all studies was 2.84 months (range: 1.9-6.5). PD-1 inhibitors had a lower rate of RECIST Progressive Disease than PD-L1 inhibitors (42.61%, 95% confidence interval [CI]: 36.29-49.06 vs. 56.79%, 95% CI: 49.18-64.19,P < 0.001). The rate of TRAEs of any grade (62.7%, 95% CI: 59.8-65.6) did not differ.Conclusions: Meta-analysis shows the efficacy of PD-1 and PD-L1 inhibitors in HNSCC and suggests a possible difference in certain RECIST criterion between PD-1 and PD-L1 inhibitors. Future work to investigate the clinical significance of these findings is warranted.
